OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma

In collaboration with Dana Farber Cancer Institute, kidney cancer research aims to enhance metastatic patient management by pinpointing biomarker to optimize clinical decision-making

On June 2, 2024, OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, announced a research study with Dana-Farber Cancer Institute, a world leader in adult and pediatric cancer treatment and research, to identify biomarkers for renal cell carcinoma (RCC), a type of kidney cancer.

Login Or Register To Read Full Story